IFNG and neoplasm: Schoenfeld et al. categorized these acquired drug resistance aspects as (1) loss of antigen presentation, (2) loss of IFN-γ signaling, (3) loss of neoantigens, (4) tumor cell-mediated immunosuppression and immune escape, and (5) other immunosuppressive ligands [172].